Expertise in
38
conditions

Dr. Scott Plotkin

Neurology
Office
55 Fruit St # 9, 
Boston, MA 
Offers Telehealth
Expertise in
38
conditions
Office
55 Fruit St # 9, 
Boston, MA 

Overview

Scott Plotkin is a Neurologist practicing medicine in Boston, Massachusetts.

Dr. Plotkin is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis, and Acoustic Neuroma.

He is actively involved in clinical research, co-authoring 192 peer reviewed articles and participating in 12 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in MA

Hospital Affiliations

Massachusetts General Hospital
Massachusetts Eye And Ear Infirmary -
Brigham And Women's Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Office
55 Fruit St # 9, Boston, MA 02114

Additional Areas of Focus

Dr. Plotkin has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas
Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Drug
Study Drug: Aspirin
Study Phase: Phase 2
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drug: Binimetinib
Study Phase: Phase 2
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
Enrollment Status: Unknown
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Tanezumab
Study Phase: Phase 2
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
Enrollment Status: Terminated
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation
A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation
Enrollment Status: Unknown
Publish Date: October 18, 2022
Intervention Type: Drug
Study Drug: AZD2014
Study Phase: Phase 2
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)
Enrollment Status: Terminated
Publish Date: October 27, 2021
Intervention Type: Procedure, Device
Study Phase: Not Applicable
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Enrollment Status: Completed
Publish Date: February 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

192 Total Publications

Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 10, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Patrick Y. Wen
Neurology
Expertise in
26
conditions
Dr. Patrick Y. Wen
Neurology
Referral may be required

Dana-Farber Cancer Institute, Center For Neuro-Oncology

450 Brookline Avenue, 
Boston, MA 
 (2.7 miles away)
617-632-2166
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Patrick Wen is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Wen is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Wen is board certified in Neurology and Neuro-Oncology.

Expertise in
76
conditions
Dr. Jeremy Schmahmann
Neurology
Expertise in
76
conditions
Dr. Jeremy Schmahmann
Neurology
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-726-3216
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Schmahmann is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Schmahmann is highly rated in 76 conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia, Acute Cerebellar Ataxia, Olivopontocerebellar Atrophy, Drug Induced Dyskinesia, and Gastrostomy.

Expertise in
27
conditions
Dr. Justin Jordan
Neurology
Expertise in
27
conditions
Dr. Justin Jordan
Neurology
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-8770
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Justin Jordan is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Jordan is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Tissue Biopsy.

Frequently Asked Questions about Dr. Scott Plotkin

How do I make an appointment with Dr. Scott Plotkin?

You can book an appointment with Dr. Scott Plotkin by calling their office at 617-724-8770. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Scott Plotkin a top-rated expert for Schwannomatosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Scott Plotkin is classified as an Elite expert for Schwannomatosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Scott Plotkin specialize in?

While Dr. Scott Plotkin is a Neurology, they have specific expertise in Schwannomatosis, Neurofibromatosis Type 2 (NF2), and Neurofibromatosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Scott Plotkin participate in research or clinical trials?

Yes. Dr. Scott Plotkin has published 192 articles and abstracts on conditions like Schwannomatosis. You can view a list of Dr. Scott Plotkin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Scott Plotkin accept my insurance?

Dr. Scott Plotkin accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 617-724-8770 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Plotkin's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 15 Distinguished Conditions
View All 14 Advanced Conditions
View All 52 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile